European Neurology · 2007 · 65 citations · 10 references
MedicinePharmacologyPharmacotherapyEpilepsyPharmacogeneticsPharmacogenomicsAntiepileptic PharmacotherapyDrug Transporter GeneticsDrug-resistant EpilepsyEpilepsy GeneticsGenetic EpilepsiesPharmacogenetic TestingControl Group DesignDrug-resistant Epilepsy GeneticsMatched Control GroupPathomechanisms Of Genetic EpilepsyPharmacogenetics In Epilepsy
BACKGROUND AND AIMS: We investigated the prevalence of this multidrug resistance 1 gene (MDR1) polymorphism in drug-responsive versus drug-resistant epilepsy patients treated with carbamazepine (CBZ), which is a substrate of this protein. METHODS: We genotyped the C3435T variant of MDR1 in 97 patients treated with CBZ monotherapy who had been on stable doses for more than 1 month. Our control group included 174 healthy individuals. Plasma CBZ concentrations were also measured using fluorescence polarization immunoassay. RESULTS: We could not demonstrate any statistically significant relationship with the genotypes among drug-resistant patients (n = 44). The frequency of the homozygous mutant (TT) genotype was 15% in drug-responsive patients, 11.3% in drug-resistant patients and 25.8% in the control group. We also did not observe any significant correlation between the presence of a specific allele and CBZ plasma level/dose index. CONCLUSION: Our study did not support any significant association between the MDR1 (C3435T) polymorphism and resistance to CBZ in epilepsy patients from Turkey.
10
Sven Hoffmeyer, Oliver Burk, Oliver von Richter et al. · Proceedings of the National Academy of Sciences · 2000 · 2.4K citations
Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines
John R. Riordan, Kathryn L. Deuchars, Norbert Kartner et al. · Nature · 1985 · 841 citations
Failure to confirm association of a polymorphism in <i>ABCB1</i> with multidrug-resistant epilepsy
Nigel CK Tan, Sarah E. Heron, Ingrid E. Scheffer et al. · Neurology · 2004 · 211 citations
Medicine, Genetics, Pharmacology +17